News Releases

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

2012201120102009200820072003

Jun 13, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator in...

More
Jun 11, 2019

Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with an immunology expert and company management on Thursday, June 13, 2019 at 8:00...

More
Jun 1, 2019

Nektar Therapeutics (Nasdaq: NKTR) announced today that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting in Chicago,...

More
May 23, 2019
Key Assets will Include NKTR-181, a Novel, First-in-Class, Investigational Opioid

Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will be responsible for launch...

More
May 15, 2019

Nektar Therapeutics (Nasdaq: NKTR) today announced five abstracts accepted for presentation at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from...

More
 

 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide